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Natural killer (NK) cells are a subset of lymphocytes capable of
killing tumor cells, virally infected cells and antibody-coated cells.
Dibutyltin (DBT) dichloride is an organotin used as a stabilizer in
polyvinylchloride (PVC) plastics and as a deworming product in
poultry. DBT may leach from PVC water supply pipes and
therefore poses a potential risk to human health. We previously
reported diminished NK cells lysis of tumor cells following
exposure to DBT in serum-free cell culture medium. However,
under in vivo conditions, circulating cells will be exposed to DBT
in the presence of 100% plasma; thus we investigated whether
serum supplementation and incubation time modulates DBT
effects on NK cell killing and the accumulation of DBT in freshly
isolated NK cells, to determine whether a serum-free model
accurately predicts possible effects of DBT on human NK cells
under in vivo conditions. Lytic function was decreased by
approximately 35% at an intracellular DBT (DBTi) concentration
of 200mM and nearly complete loss of lytic function was observed
at DBTi above 300mM for one h. However, an intracellular
concentration of 50mM DBT, achieved over 24 h of exposure in
50% serum, reduced lytic function by 50%. Thus, conditions that
reflect prolonged contact with circulating DBT, in the presence of
serum, suggest that NK cell activity is decreased at lower DBTi.
These data indicate that the model is useful in predicting potential
human effects of relatively low DBTi concentrations.
Key Words: dibutyltin dichloride; natural killer cells;
immunotoxicity; in vitro methods.
Dibutyltin (DBT) is used as a stabilizer in the production of
polyvinylchloride (PVC) plastics (Roper, 1992; Yamada et al.,
1993) and as a deworming agent in poultry. DBT has been
reported to leach from PVC pipes into finished drinking water
(Sadiki et al., 1996), into beverages stored in PVC pipes during
manufacture (Forsyth et al., 1992a, b) and as a contaminant in
some poultry products (Epstein et al., 1991). Additionally,
DBT contaminates seafood (Rantakokko et al. 2006; Ueno
et al., 1999) and measurable levels of butyltins have also been
found in human blood and liver (Kannan et al., 1999; Nielsen
and Strand, 2002; Whalen et al., 1999). As mandated by the
Safe Drinking Water Act, the U.S. Environmental Protection
Agency included DBT on the Candidate Contaminant List
2 because of likely human exposure via drinking water and the
potential to adversely affect the immune system.
Exposure to DBT has been reported to disrupt normal
embryonic development and has been associated with a variety
of birth defects in rats including cleft mandible and fused ribs
(Ema et al., 1996; Noda et al., 1993). Exposure has also been
associated with atrophy of the thymus and pancreatitis in rats
(Merkord et al., 1997; Pieters et al., 1994). Animal studies also
indicate that organotins, including DBT and tributyltin (TBT),
diminish immune function, including natural killer (NK) cell
activity (Seinen et al., 1977; Vos et al., 1990).
NK cells are a subset of lymphocytes that are capable of
killing tumor cells, virally infected cells and antibody-coated
cells. NK cells are capable of killing tumor cells without prior
sensitization, putting them in the forefront of lymphocyte
defense against tumor cells and virally infected cells (Lotzova,
1993, Vivier et al., 2004). The earliest and possibly pre-
dominant defense against tumor cells has been attributed to NK
cells (Lotzova, 1993; O’Shea and Ortaldo, 1992; Trinchieri,
1989). NK cells are defined by the absence of the T-cell
receptor/CD3 complex and by the presence of CD56 and/or
CD16 on the cell surface. They are responsible for limiting the
spread of blood borne metastases, as well as limiting the
development of primary tumors (Hanna, 1980; Kiessling and
Haller, 1978). NK cells also play a central role in immune
defense against viral infection as evidenced by greatly increased
incidence of viral infection seen in individuals where the NK
subset of lymphocytes is completely absent (Biron et al., 1989;
Fleisher et al., 1982). Therefore, any chemical that can affect
the ability of NK cells to recognize and lyse a target cell, could
potentially increase the risk of tumors and viral infections.
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In vitro exposure of human NK cells to DBT in serum-free
medium dramatically inhibits their lytic function (Whalen
et al., 1999, 2002a, b). This decrease in lytic function was
accompanied by a decreased capacity of NK lymphocytes to
bind tumor targets when the cells were exposed to DBT for
24 h. Further studies reported that ATP levels as well as levels
of several functionally important proteins were decreased in
NK cells exposed to DBT in serum-free medium (Catlin et al.,
2005; Dudimah et al., 2007a; Odman-Ghazi et al., 2003;
Whalen and Loganathan, 2001).
Published reports (Harrill et al., 2005; Mundy et al., 2004;
Seibert et al., 2002) suggest that the presence or absence of
serum (or serum albumin) may influence intracellular accumu-
lation of xenobiotics under in vitro conditions, and that
intracellular chemical concentrations may provide a useful
metric for risk assessment. Thus, the goal of the current study
was to determine the accumulation of DBT in NK cells under
conditions of no serum, 10% serum, and 50% serum, as well as
the effects of serum on the ability of NK cells to lyse tumor
cells. This information is essential in evaluating the risk that
environmental levels of DBT may pose to immune function.
MATERIALS AND METHODS
Isolation of NK cells. Highly purified NK cells were isolated from buffy
coat preparations (American Red Cross, Portland, OR) using a rosetting
procedure. Buffy coats were mixed with 1 ml of RosetteSep human NK cell
enrichment antibody cocktail (StemCell Technologies, Vancouver, British
Columbia, Canada) per 30 ml of buffy coat. The mixture was incubated for 40
min at room temperature (~25C) with periodic mixing. Following the
incubation, 5 ml of the mixture was layered onto 4 ml of Ficoll-Hypaque (1.077
g/ml) (MP Biomedicals, Irvine, CA) and centrifuged at 1200 x g for 30 min.
The cell layer was collected and washed twice with phosphate buffered saline,
pH 7.2, and cultured in basic medium (RPMI-1640 supplemented with 2mM
l-glutamine, 50 U penicillin G and 50 lg streptomycin/ml) plus 10% heat-
activated bovine calf serum (BCS), at 1 million cells/ml for up to 16 h before
exposure to DBT. The resulting cell preparation was >95% CD16þ, CD56þ, 0%
CD3þ by fluorescence microscopy and flow cytometry (Whalen et al., 2002a).
Chemical preparation. 14C-DBT was produced by RTI International
(Research Triangle Park, NC) and was generously donated by Dr Tom Burka,
National Institute of Environmental Health Sciences, National Institutes of
Health. DBT was purchased from Sigma-Aldrich (St Louis, MO). Stock solutions
of 14C-DBT and DBT were made in dimethylsulfoxide (DMSO) (Sigma-Aldrich)
and diluted into the appropriate cell culture media. Final DMSO concentrations
were the same in all cultures across all concentrations of DBT.
Cell treatments. Pooled human type AB serum (Cellgro, Mediatech, Inc.,
Herndon, VA), without heat inactivation and from a single lot, was used in all
experiments. Purified NK cells were separated by centrifugation from BCS-
supplemented basic medium and transferred to basic medium containing 0.5%
gelatin, 10% human serum, or 50% human serum. NK cells (at a concentration
of 1.5 million cells/ml) were then exposed to varying concentrations of 14C-
DBT (DBT in the medium; DBTm) from 0.5 to 10lM for 1 h. Concentrations
were chosen based on previous in vitro studies and because levels as high as
0.3lM DBT have been measured in human blood (Catlin et al., 2005; Dudimah
et al., 2007a; Whalen et al., 1999, 2002a, b). Additionally, NK cells were
exposed to the following: 5lM 14C-DBT for 5, 10, 30, 60, and 120 min; 5lM
14C-DBT for 24 h; 1lM 14C-DBT for 24 h; and 5lM 14C-DBT for 1 h followed
by 24 h in DBT-free medium. Accumulation of 14C-DBT under these
conditions was measured as described below. NK cells were also exposed to
unlabeled DBT under the same conditions as described for 14C-DBT and then
tested for the effect on lytic function as described below. In all experiments, cell
viability was assessed after incubation by 14C-DBT trypan blue dye exclusion;
none of the treatments affected cell viability.
14C-DBT accumulation. Following the exposures, the cells were centri-
fuged and the supernatant was removed and placed in an appropriately labeled
scintillation vial. The cell pellet was then resuspended in 500 ll of medium and
centrifuged. The supernatant was removed and added to the scintillation vial
containing the initial supernatant. This process was repeated. Following the
wash step, 100 ll of 0.1M NaOH was added to the pellet and the dissolved
pellet was transferred to a scintillation vial. The total radioactivity added to the
cells at a given DBT concentration was determined by adding that same amount
of 14C-DBT to a separate scintillation vial and counting it with the samples.
Results are given as lM DBT accumulated in the cells (DBTi). The total
volume of the cells was estimated using the number of NK cells that were
present and multiplying that number by the estimated volume of an individual
NK cell (approximately 7.35 3 1010 ml, assuming a diameter of 15lM).
Unless stated otherwise, all results are presented as the mean ± SEM.
Cytotoxicity assay. The ability of NK cells to lyse tumor cells was
measured using a 51Cr release assay (Whalen, 1997; Whalen et al., 1999). The
target (T) cell in all cytotoxicity assays was the NK-susceptible K562 (human
chronic myelogenous leukemia) cell line. K562 cells were incubated with 51Cr
(Perkin-Elmer Life Sciences, Boston, MA) in 0.2–0.5 ml of BCS for 1–1.5 h at
37C in air/CO2 (19:1). Following this incubation, the target cells were washed
twice with serum-free medium. NK cells (100 ll) were added to the wells of
round-bottom microwell plates. Dilutions of NK effector (E) cells were
prepared to produce final E:T cell ratios of 12:1 (1.2 3 105 E/100 ll), 6:1 (0.6
105/100 ll) and 3:1 (0.3 3 105/100 ll); each ratio was tested in triplicate.
Target cells were added (1 3 104 in 100 ll) to each well of the microwell plate
and the plate was centrifuged at 300 3 g for 3.5 min and incubated for 2 h at
37C (air/CO2, 19:1). After incubation, a 0.1-ml aliquot of the supernatant was
collected and counted for radioactivity for 60 sec in a Packard COBRA gamma
radiation counter (Packard Instrument Co., Meriden, CT). Target lysis was
calculated as follows: 100 3 [(test c.p.m  spontaneous c.p.m.)/maximum
c.p.m.  spontaneous c.p.m.)]. Maximum release was determined by adding
100 ll of 10% Triton X-100 to wells containing only target cells; spontaneous
release was determined by counting the supernatant of wells containing target
cells in medium alone.
Statistical analysis. Data from experiments that evaluated effects of
serum, DBTm or incubation time on DBTi accumulation and NK cell lytic
activity were analyzed by comparing the slopes of dose-response curves, using
the General Linear Model (GLM; SAS, Cary, NC). A contrast statement was
used within the GLM to test the null hypothesis that Ho: B1 ¼ B2 ¼ B3, where
B ¼ the slope of the line for each serum concentration. This approach was
chosen to evaluate treatment effects over the range of independent variables by
determining whether the slopes of the lines differed, rather than a point-
by-point analysis using ANOVA. However, ANOVA (SAS) was used when it
was necessary to compare mean values. When ANOVA indicated a statistically
significant treatment effect, individual post hoc comparisons were made using
the least squares means t-test. Differences between groups was considered
significant when the value of p was < 0.05.
RESULTS
Accumulation of DBT by NK Cells in Serum-Free Medium,
10% Human AB Serum-Containing Medium, and 50%
Human AB Serum-Containing Medium
Intracellular accumulation of DBT (DBTi) in each medium
was tested in cells from the same donor to eliminate differences
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due to variables other than the composition of the medium and
was repeated with cells from three separate donors. There was
no significant binding of the DBT to the plastic tubes at any of
the concentrations of DBT or at any concentration of serum.
Cell viability was not affected by any treatment. The slopes of
the DBT accumulation curves after 1 h of incubation in the
presence of 0.5–10lM 14C-DBT differed, indicating a signifi-
cant effect of serum supplementation (Fig. 1). Comparison of
DBTi curves at 0, 10% and 50% serum supplementation
indicated that DBTi was similar at 0 and 10% and 0 and 50%,
and significantly different (p < 0.01) at 10% and 50%. The
results suggest that DBTi accumulation was less at a serum
concentration approaching those in vivo, compared with those
typically used in tissue culture. However, the lack of
statistically significant differences between serum- and 40.5%
gelatin-supplemented cultures are difficult to interpret, and may
indicate that 1 h of incubation was not sufficient to determine
the effects of serum supplementation on DBT uptake.
A time curve of DBT accumulation at 5lM DBT from 10 to
120 min is shown in Figure 2. Intracellular concentrations of
DBT in NK cells incubated in serum-free medium were 165 ±
9lM after 10 min and 396 ± 31lM after 120 min. In medium
containing 10% serum, DBTi concentrations were 146 ± 9lM
and 318 ± 16lM after 10 and 120 min, respectively. The slopes
of the curves for 0 and 10% serum indicated a significant
effect of incubation time (p < 0.0001). However, in the
presence of 50% serum, DBTi was 175 ± 17lM after 10 min
and 185 ± 9lM after 120 min, and the slope of the curve was
not different from zero; DBTi peaked at 30 min, and did not
increase thereafter. The slopes of the curves for 0 and 10%
serum supplementation indicated a significant difference in
uptake in cultures compared with medium supplemented with
50% serum (p < 0.01), and no significant difference between
the 0 and 10% serum.
The effect of serum concentration on intracellular accumu-
lation of DBT after 24 h in culture was also examined (Fig. 3).
Incubation with 1lM DBT in medium supplemented with 0, 10%
and 50% serum produced DBTi of 145 ± 11lM, 84 ± 8lM,
and 50 ± 4lM, respectively. Cells cultured with 5lM DBT in
0, 10% or 50% human AB serum-containing medium accumu-
lated 496 ± 33lM, 310 ± 30lM, and 214 ± 10lM, respectively
(Fig. 3A). Slopes of the accumulation curves indicated
a significant effect of serum supplementation (p < 0.0001),
which varied among DBTm (p < 0.0001); comparison of 1 and
5lM DBTm slopes indicated a significant difference in DBTi
(p < 0.001). The presence of 10% serum in the medium
decreased uptake by 38% and 50% serum decreased uptake by
57% compared with 0% serum. These results indicated that as
the concentration of serum in the medium increased there was
a significant decrease in the accumulation of DBT in the NK
cells at a given DBTm. Furthermore, DBTi was similar at
a given DBTm/serum concentration at 1 and 24 h (Fig. 3B).
To determine whether accumulated DBT remains in the cell
or is lost to DBT-free culture medium, cells were incubated for
1 h in medium containing 5lM DBT and 0, 10% or 50%
serum. Cells were then washed and recultured in medium
supplemented with the same serum concentration as before.
Intracellular concentrations at 24 h were 168 ± 36, 64 ± 11, and
31 ± 4lM, respectively, after culture in serum-free, 10 and
50% serum (Fig. 4). DBTi was greater in NK cells recultured in
serum-free medium than in medium supplemented with 10%
(p < 0.003) or 50% (p < 0.0002) serum.
FIG. 1. Accumulation of DBT in human NK cells exposed to 0.5–10lM
DBT for 1 h in three different media. (Filled diamond) Serum-free medium
(serum was replaced by 0.5% gelatin); (filled square) medium containing 10%
human AB serum; (filled triangle) medium containing 50% human AB serum.
Results were combined from separate experiments using different donors
(triplicate determinations for each experiment). *Slopes of accumulation curves
are significantly different p < 0.05.
FIG. 2. Accumulation of DBT in human NK cells exposed to 5lM DBT
for 10, 30, 60, and 120 min in three different media. (Filled diamond) Serum-
free medium (serum was replaced by 0.5% gelatin); (filled square) medium
containing 10% human AB serum; (filled triangle) medium containing 50%
human AB serum. Results were combined from separate experiments using
different donors (triplicate determinations for each experiment). A: Significant
(p < 0.0001) effect of incubation time on DBTi; B: no significant (p > 0.05)
effect of incubation time on DBTi, significant (p < 0.01) difference in DBTi at
0 and 10% serum supplementation.
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Comparison of 14C-DBT and DBT Potency to Decrease NK
Cell Lytic Function
To determine if radiolabeled and nonlabeled DBT were
equally effective at diminishing the ability of NK cells to
destroy K562 tumor cells, serum-free cultures were exposed to
5 and 10lM 14C-DBT and 12C-DBT for 1 h or to 0.5 and 1lM
14C-DBT and 12C-DBT for 24 h, washed, and cultured with
target cells. Exposure to 12C- and 14C-labeled DBT signifi-
cantly and equally decreased NK cell activity (data not shown).
NK Cell Activity following DBT Exposure in Serum-Free,
10 and 50% Human AB Serum-Containing Media
Figure 5 shows the effects of various exposures to DBT in
serum-free and serum-supplemented culture medium on lytic
activity of NK cells, expressed as percent of control. There was
an overall effect (p < 0.01) of DBT exposure for 1 h at all
serum concentrations; at the highest DBTm, NK activity was
suppressed by 95%. Slopes did not differ between serum-free
and 10% serum-containing medium; a trend was observed
when the slopes of the zero and 50% serum curves (p ¼ 0.054)
and the 10 and 50% serum curves (p ¼ 0.056) were compared
(Fig. 5A).
The effects of a 24-h exposure to 0.25, 0.5, and 1lM DBT in
the three types of medium are shown in Figure 5B. In the
absence of serum, the slope of the inhibition curve for all
concentrations of DBTm was similar; that is, all concentrations
of DBTm significantly reduced NK cell activity. In contrast,
there was a significant effect of DBTm in the presence of 10%
(p ¼ 0.0062) or 50% (p ¼ 0.001) serum. The slopes of the
curves differed significantly between 0 and 50% (p < 0.0001)
and 10 and 50% serum (p ¼ 0.001). These results indicate that
the presence of serum in the medium reduced the inhibitory effect
of DBT on NK cell activity, and that 50% serum supplementation
had a greater protective effect than did 10% serum.
Data presented in Figure 4 indicate that the presence of
serum in DBT-free medium increased the efflux of DBT from
the intracellular compartment into the medium when cells were
cultured for an additional 24 h. Cells subjected to the same
loading/DBT-free culture scheme were incubated with target
cells to determine whether culture in the absence of DBT for 24 h
affected DBT-mediated suppression of NK cell activity and to
assess the modulating effect, if any, of serum supplementation.
There was an overall effect of serum concentration (p <
0.0001) on inhibition of NK cell activity by DBT (Fig. 5C), but
no significant difference in NK cell activity of cells cultured for
24 h in serum-free or 10% serum-supplemented media.
However, significantly less suppression of NK cell activity
occurred in cells cultured for 24 h in medium supplemented
with 50% serum (Fig. 5C). Reducing DBTi by culture in the
presence of physiological serum concentrations partially
reversed suppressed lytic activity.
FIG. 3. Accumulation of DBT in human NK cells exposed to the
following: (A) 1 (filled square) or 5 (filled diamond) lM DBT for 24 h in three
different media. (A, B) Significant (p < 0.0001) effect of serum concentration
on DBTi; different letters indicate significant (p < 0.0001) difference in DBTi
at 1 and 5lM DBTm. (B) Comparison of DBTi at 1 or 5lM DBTm at three
levels of serum supplementation for 1 or 24 h.
FIG. 4. DBTi following incubation with 5lM DBTm for 1 h followed by
24 h in three different DBT-free media. Results were combined from separate
experiments using different donors (triplicate determinations for each
experiment). Groups designated with different letters are significantly (p <
0.003) different from the others.
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Figures 6A and 6B plot the relationship between intracellular
concentrations of DBT and the loss of lytic function at 1 h and
24 h, respectively. These plots indicate that a complete loss of
lytic function occurs at 1 h when the intracellular concentration
of DBT reaches about 400lM. However, after 24 h, a
concentration of between 50 and 100lM was associated with
complete loss of lytic function.
DISCUSSION
Recent emphasis on the development of high throughput
screening methods, and the use of in vitro models to evaluate
mode and mechanism of action, underscore the importance of
determining whether culture conditions affect either the
experimental outcome or interpretation of results. Traditional
techniques often include supplementation of the culture
medium with 10% serum, and other models exclude serum as
FIG. 5. Effect of DBT on NK cell lytic function. (A) One-hour exposure to
2.5–10lM DBT in medium supplemented with zero (filled diamond), 10%
(filled square), or 50% (filled triangle) serum; (A) significant (p < 0.01) effect
of DBTm on lytic function; (B) 24-h exposure to 0.25–1lM DBT for 24 h in
medium supplemented with zero (filled diamond), 10% (filled square), or 50%
(filled triangle) serum; slopes marked with different letters are significantly
different from each other. (C) One-hour exposure to 5lM DBT followed by 24 h
in three different DBT-free media. Results from representative experiments
were repeated in experiments using different donors (triplicate determinations),
12:1 E:T. *Significantly different from serum-free and 10% media.
FIG. 6. Relationship between loss of lytic function and the concentration
of DBT in NK cells. (A) Percent decrease in lytic function after 1 h at a given
exposure concentration of DBT is plotted as a function of the DBT concen-
tration in the NK cells after 1 h at that same exposure concentration. The values
of DBT concentration in NK cells were taken from Figure 1. Values for percent
decrease in lytic function were derived from Figure 5A. (B) Percent decrease in
lytic function after 24 h at a given exposure concentration of DBT is plotted as
a function of the DBT concentration in the NK cells after 24 h at that same
exposure concentration. The values of DBT concentration in NK cells were
taken from Figure 3A. Values for percent decrease in lytic function were
derived from Figure 5B. Exposures were in 0, 10, and 50% serum-containing
media, as described in Figures 1 and 3.
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a supplement to prevent binding of the test substance to serum
proteins. However, published reports (Harrill et al., 2005;
Mundy et al., 2004; Seibert et al., 2002) suggest that the
presence or absence of serum (or serum albumin) may
influence intracellular accumulation of xenobiotics under in
vitro conditions. The goal of the current study was to determine
whether serum supplementation affected accumulation and loss
of DBT by NK cells and the effects of intracellular
concentrations of DBT on target cell lysis.
DBT decreased the lytic function of human NK cells when
they were exposed at concentrations ranging from 0.5 to 10lM
for 1–24 h in serum-free medium (Catlin et al., 2005; Dudimah
et al., 2007a; Whalen et al., 1999, 2002a, b). The lower
concentrations used in the studies were similar to those
detected in human blood samples (levels as high as 0.3lM;
Whalen et al., 1999). However, circulatory transport of DBT
occurs in the presence of 50–60% serum. It was therefore
essential to determine whether the presence of serum affects
DBTi concentration in NK cells as the first step in clarifying
how well in vitro DBTm concentrations predict DBTi
accumulation and subsequent adverse biological effects in vivo.
Intracellular concentrations of DBT increase rapidly (40- to
100-fold compared with DBTm) and are a function of DBT and
serum concentrations in the culture medium. DBTi reaches
a maximum relatively soon after DBT is added (Fig. 3B) but
probably not as a result of a saturation event, as DBTi was
greater at 5 than at 1lM DBTm. The mechanism(s) that limits
DBTi at a given DBTm is unknown; however it is independent
of time, but not of physiological levels of serum. Serum
supplementation reduced intracellular accumulation of DBT,
suggesting that binding to extracellular (serum) proteins
decreases movement across the cell membrane. Nevertheless,
concentrations of DBT achieved after as few as 30 min of
culture in 50% serum (approximately 200lM, Fig. 2) was well
within the range of DBTi that reduced target cell killing
by nearly 40% (see Fig. 6A). Serum also appeared to enhanced
the movement of DBT out of cells cultured in DBT-free
medium (Fig. 4), suggesting that DBT may be exported,
actively or passively, and is bound by serum proteins and
therefore unavailable for reuptake. However, it is also possible
that the presence of serum in DBT-free medium activated
metabolism of DBT to labeled metabolites that were then
transported out of the cell. In either case, the presence of serum
under DBT-free conditions appears to have significantly
decreased intracellular concentrations of DBT. We have
previously shown that the magnitude of suppressed NK
cell activity induced by 1-h exposure to DBT was similar in
cells evaluated immediately after exposure and those cultured
for up to 6 days in the absence of DBT (Whalen et al., 2002a),
although those experiments did not determine whether DBTi
concentrations were maintained over time. However, in the
previous study, cells were recultured in serum-free medium,
and movement of DBT from the intracellular compartment
was therefore not influenced by events that, in the current
study, led to lower DBTi. Serum effects on DBT accumulation
were less dramatic than those reported with 1lM PDBE-47;
PDBE-47 accumulation was diminished from about 80-fold in
serum-free medium to about 20-fold when the exposure
medium contained 10% serum (Mundy et al., 2004). PDBE-
47 is a very lipophilic compound with a Kow of 6.5 (European
Union, 2001), whereas DBT is far less lipophilic, with
a reported Kow of 0.05 (Government of Canada, 1993). The
less lipophilic nature of DBT may explain why its accumula-
tion in cells was less affected by the presence of serum than
was that of PDBE.
Previous serum-free in vitro studies indicate that equivalent
inhibition of NK target cell lysis occurs at lower medium
concentrations when incubation time is increased from 1 h to
24 h; cytotoxicity was reduced by approximately 80%
following 1 h exposure to 10lM DBT or 24 h exposure to
1lM (Catlin et al., 2005; Dudimah et al., 2007a; Whalen et al.,
1999). The current study indicates that duration of exposure
influences the magnitude of effects and establishes that DBTi is
associated with decreased function following brief or extended
exposure. For example, a DBTi of 200lM decreased lytic
function by approximately 35% and DBTi above 300lM
resulted in nearly complete loss of lytic function within 1 h
(Fig. 6A). However, an intracellular concentration of 50lM
DBT, achieved over 24 h of exposure to 1lM DBT in 50%
serum, reduced lytic function by 50% (Fig. 6B). Human studies
indicate that DBT exposure occurs at relatively low levels, over
an extended period (Kannan et al., 1999; Nielsen and Strand,
2002; Whalen et al., 1999) and the results for 24 h, 1lM
exposure from the current study indicate that significant
reduction of lytic function occurs with longer exposure times,
at lower DBTi, than suggested by the one h exposure model.
Additional work must be done to further refine the relationship
between exposure time, DBTi concentration, targeting of
biomolecules and loss of NK cell activity. However, our
results do suggest that reduced NK cell cytotoxic function is
not a threshold-type effect in which NK cell activity is
permanently reduced when a critical level of DBT has
accumulated. Rather, defects in cellular metabolism or lytic
protein synthesis or expression appear to accumulate over time,
thus reducing cellular function.
Preferential accumulation of DBT within NK cells suggests
that intracellular components bind DBT. TBT, a close
structural relative of DBT, binds with high affinity to ATP
synthase (Aldridge, 1976; Matsuno-Yagi and Hatefi, 1993; von
Ballmoos et al., 2004) and decreases ATP levels in human NK
cells (Dudimah et al., 2007b). DBT, as does TBT, appears to
interfere with the function of ATP synthase (Cain et al., 1977),
decreases ATP in NK cells (Dudimah et al., 2007a) and may
associate with sulfhydryl-containing cellular components such
as dihydrolipoate (Cain et al., 1977), suggesting that DBT may
affect NK cell function by interfering with energy metabolism.
Recent studies indicate that a 24-h exposure to 1.5lM DBT in
serum-free medium reduced the levels of the essential NK
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cytolytic proteins, granzyme B and perforin, by 62 and 49%,
respectively (Catlin et al., 2005).
In summary, the current study suggests that, under in vivo
conditions (i.e., in the presence of serum), DBTi accumulation
will be attenuated, and less will accumulate than predicted by
the serum-free 24 h in vitro model. However, intracellular
accumulation in medium containing 1 or 5lM DBT and 50%
serum was sufficient to dramatically reduce target cell killing.
These studies also demonstrated that that longer contact time
with DBT had a greater effect on cell function, at lower
intracellular concentrations. Thus, both DBTi concentration
and exposure time are important factors in reducing NK cell
activity. Depuration studies (DBT exposure for 1 h followed by
incubation for 24 h in DBT-free medium) indicated that
a portion of accumulated DBT is lost when cells are cultured in
the absence of DBT, and that an inverse relationship exists
between medium serum concentration and the proportion lost,
although binding to intracellular components is not entirely
reversible. Extrapolating our results to in vivo exposure, the
data suggest that as body burdens decrease, DBT levels in
previously exposed cells may decrease rather rapidly. Never-
theless, our results suggest that even as body burdens fall, DBT
may accumulate in cells at levels sufficient to compromise NK
cell function. Finally, the inhibitory effects of serum on DBT
and PBDE-47 (Mundy et al., 2004) and other studies that have
evaluated intracellular vs. media concentrations of xenobiotics
(Harrill et al., 2005) clearly indicate that medium concen-
trations of xenobiotics do not necessarily predict the actual
dose to the cell. Our studies support this conclusion, in that we
found a 40- to 80-fold difference between intracellular versus
medium concentrations. However, our studies indicate that
exposure time, and thus cumulative effects, are critical factors
that may ultimately determine the relationship between
intracellular concentration and cell function.
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